Zenas BioPharma (NASDAQ:ZBIO) Price Target Lowered to $41.00 at Citigroup

Zenas BioPharma (NASDAQ:ZBIO) had its price objective cut by investment analysts at Citigroup from $43.00 to $41.00 in a research note issued on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Citigroup’s target price indicates a potential upside of 75.06% from the stock’s previous close.

Other analysts have also recently issued reports about the stock. Guggenheim boosted their price objective on shares of Zenas BioPharma from $45.00 to $55.00 and gave the company a “buy” rating in a research note on Monday. Wall Street Zen upgraded Zenas BioPharma from a “sell” rating to a “hold” rating in a report on Saturday, February 21st. Morgan Stanley boosted their price target on Zenas BioPharma from $19.00 to $21.00 and gave the company an “equal weight” rating in a research report on Tuesday. HC Wainwright restated a “buy” rating and set a $44.00 price target on shares of Zenas BioPharma in a research note on Tuesday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Zenas BioPharma in a report on Monday, December 29th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Zenas BioPharma has an average rating of “Moderate Buy” and an average price target of $44.14.

Zenas BioPharma Trading Up 0.8%

Shares of ZBIO traded up $0.19 during mid-day trading on Tuesday, hitting $23.42. The company had a trading volume of 122,956 shares, compared to its average volume of 927,645. Zenas BioPharma has a 1-year low of $6.11 and a 1-year high of $44.60. The business’s 50-day simple moving average is $22.61 and its 200-day simple moving average is $27.12. The stock has a market cap of $1.26 billion, a PE ratio of -3.30 and a beta of -1.96. The company has a quick ratio of 5.66, a current ratio of 5.66 and a debt-to-equity ratio of 0.37.

Zenas BioPharma (NASDAQ:ZBIO) last issued its quarterly earnings results on Monday, March 16th. The company reported ($4.54) EPS for the quarter, missing the consensus estimate of ($1.22) by ($3.32).

Insider Activity

In related news, Director Hongbo Lu acquired 25,985 shares of the company’s stock in a transaction on Wednesday, February 11th. The shares were purchased at an average price of $22.50 per share, for a total transaction of $584,662.50. Following the purchase, the director owned 347,968 shares in the company, valued at $7,829,280. This represents a 8.07% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Leon O. Moulder, Jr. bought 57,000 shares of the business’s stock in a transaction on Monday, February 2nd. The stock was bought at an average price of $17.96 per share, with a total value of $1,023,720.00. Following the transaction, the chief executive officer owned 423,155 shares in the company, valued at approximately $7,599,863.80. This represents a 15.57% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired 202,845 shares of company stock worth $3,747,185 in the last 90 days. Company insiders own 16.50% of the company’s stock.

Institutional Trading of Zenas BioPharma

Several large investors have recently added to or reduced their stakes in ZBIO. PNC Financial Services Group Inc. boosted its stake in shares of Zenas BioPharma by 41.2% during the 2nd quarter. PNC Financial Services Group Inc. now owns 9,179 shares of the company’s stock worth $89,000 after acquiring an additional 2,679 shares in the last quarter. Geode Capital Management LLC boosted its position in Zenas BioPharma by 4.6% during the second quarter. Geode Capital Management LLC now owns 373,617 shares of the company’s stock worth $3,621,000 after purchasing an additional 16,461 shares during the period. Intech Investment Management LLC grew its holdings in Zenas BioPharma by 13.9% during the second quarter. Intech Investment Management LLC now owns 13,206 shares of the company’s stock valued at $128,000 after purchasing an additional 1,607 shares during the last quarter. Rhumbline Advisers raised its position in shares of Zenas BioPharma by 71.3% in the second quarter. Rhumbline Advisers now owns 19,721 shares of the company’s stock valued at $191,000 after purchasing an additional 8,207 shares during the period. Finally, Federated Hermes Inc. lifted its stake in shares of Zenas BioPharma by 60.8% in the second quarter. Federated Hermes Inc. now owns 1,861,838 shares of the company’s stock worth $18,041,000 after buying an additional 703,838 shares during the last quarter.

Key Headlines Impacting Zenas BioPharma

Here are the key news stories impacting Zenas BioPharma this week:

• Positive Sentiment: Secured up to $250 million in non‑dilutive, multi‑tranche debt financing from Pharmakon, which materially strengthens near‑term liquidity and supports upcoming regulatory filings and trials. Zenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: HC Wainwright reaffirmed a Buy rating and a $44 price target — signaling strong upside potential (large gap versus current price) and likely contributing bullish investor interest. Benzinga
• Positive Sentiment: Notable insider and institutional accumulation reported (multiple insider purchases and several large funds adding shares), which can signal management confidence and support the share price. Quiver Quantitative
• Neutral Sentiment: Company reiterated clinical and regulatory milestones (FDA/EMA submissions for obexelimab expected in 2026; ongoing/near‑term Phase‑3 activity for orelabrutinib and pipeline progress) — important catalysts but timing/outcomes remain uncertain. Corporate update & milestones
• Neutral Sentiment: Company granted inducement stock options and RSUs to new hires (235,700 options; 33,450 RSUs) — supports hiring and retention but introduces potential future dilution; viewed as operational rather than immediate material impact. Inducement Grants
• Negative Sentiment: Significant quarterly earnings miss: GAAP EPS of -$4.54 vs. consensus -$1.22 — the large shortfall raises near‑term profitability and guidance concerns and has negative implications for valuation. Earnings press release
• Negative Sentiment: Company disclosed an IPO‑related securities class action in its risk filings, which adds potential legal exposure and execution risk until resolved. TipRanks – Litigation risk

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.